[go: up one dir, main page]

MX2019007779A - Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). - Google Patents

Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).

Info

Publication number
MX2019007779A
MX2019007779A MX2019007779A MX2019007779A MX2019007779A MX 2019007779 A MX2019007779 A MX 2019007779A MX 2019007779 A MX2019007779 A MX 2019007779A MX 2019007779 A MX2019007779 A MX 2019007779A MX 2019007779 A MX2019007779 A MX 2019007779A
Authority
MX
Mexico
Prior art keywords
pefe
paniculopathy
edemato
fibrosclerotic
reduction
Prior art date
Application number
MX2019007779A
Other languages
English (en)
Other versions
MX392388B (es
Inventor
G Hart Emeigh Susan
Original Assignee
Auxilium Int Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auxilium Int Holdings Inc filed Critical Auxilium Int Holdings Inc
Publication of MX2019007779A publication Critical patent/MX2019007779A/es
Publication of MX392388B publication Critical patent/MX392388B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a un método de tratamiento o reducción de la PEFE en un paciente que comprende la administración de una o múltiples inyecciones de dosis baja de colagenasa a un área afectada por la PEFE. La invención abarca métodos en donde la dosis de colagenasa por inyección está entre alrededor de 50 a alrededor de 200 unidades ABC y/o en donde la concentración de colagenasa está entre alrededor de 50 a alrededor de 2000 unidades ABC/mililitro (ml).
MX2019007779A 2011-10-21 2012-10-19 Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe) MX392388B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549863P 2011-10-21 2011-10-21
PCT/US2012/061063 WO2013059619A1 (en) 2011-10-21 2012-10-19 Method of treating or reducing efp

Publications (2)

Publication Number Publication Date
MX2019007779A true MX2019007779A (es) 2019-09-04
MX392388B MX392388B (es) 2025-03-24

Family

ID=48141393

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007779A MX392388B (es) 2011-10-21 2012-10-19 Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe)
MX2014004792A MX2014004792A (es) 2011-10-21 2012-10-19 Metodo de tratamiento o reduccion de efp.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014004792A MX2014004792A (es) 2011-10-21 2012-10-19 Metodo de tratamiento o reduccion de efp.

Country Status (14)

Country Link
US (2) US20140335072A1 (es)
EP (2) EP2768523B1 (es)
JP (5) JP2014530873A (es)
AU (6) AU2012325941A1 (es)
BR (1) BR112014009785B1 (es)
CA (1) CA2852942C (es)
DK (2) DK3581199T3 (es)
ES (2) ES2741476T3 (es)
FI (1) FI3581199T3 (es)
HU (2) HUE044650T2 (es)
MX (2) MX392388B (es)
PL (1) PL3581199T3 (es)
PT (2) PT3581199T (es)
WO (1) WO2013059619A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013208028B2 (en) 2012-01-12 2016-04-28 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
AU2013255400A1 (en) 2012-05-01 2014-12-04 Proteolease Ltd. Methods for extracting a tooth
EP2968484B1 (en) 2013-03-15 2020-11-25 BioSpecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
CN115969318A (zh) * 2017-03-01 2023-04-18 恩多风投有限公司 用于评估和治疗橘皮组织的装置和方法
EP3601556A2 (en) 2017-03-28 2020-02-05 Endo Ventures Limited Improved method of producing collagenase
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020023406A1 (en) * 2018-07-23 2020-01-30 Nc8, Inc. Cellulite treatment system and methods
ES2989422T3 (es) 2018-07-23 2024-11-26 Revelle Aesthetics Inc Sistema de tratamiento de celulitis
MX2021003154A (es) * 2018-09-18 2021-06-23 Endo Global Aesthetics Ltd Composiciones y métodos para tratar celulitis.
KR20210113271A (ko) * 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법
EP4013319A4 (en) 2019-09-06 2023-10-04 Revelle Aesthetics, Inc. CELLULITE TREATMENT SYSTEM AND METHODS
CA3157517A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
EP3861948A1 (en) * 2020-02-10 2021-08-11 Daniel A. Del Vecchio Cellulite eradication methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
LT2422789T (lt) * 2004-05-19 2018-03-12 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injekcinės kompozicijos, apimančios natrio deoksicholiatą
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) * 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
CN102784387A (zh) * 2007-02-14 2012-11-21 友莱尔皮肤产品有限责任公司 修饰的突变体胶原蛋白酶及其在脂肪溶解和疤痕减少中的应用

Also Published As

Publication number Publication date
AU2020200763A1 (en) 2020-02-20
NZ759819A (en) 2020-11-27
AU2012325941A1 (en) 2014-05-15
BR112014009785A2 (pt) 2017-04-25
HUE063599T2 (hu) 2024-01-28
US20240216485A1 (en) 2024-07-04
JP2014530873A (ja) 2014-11-20
EP2768523A1 (en) 2014-08-27
PL3581199T3 (pl) 2023-09-11
FI3581199T3 (fi) 2023-08-18
EP3581199A1 (en) 2019-12-18
ES2953560T3 (es) 2023-11-14
EP2768523A4 (en) 2015-04-22
MX2014004792A (es) 2015-08-14
PT2768523T (pt) 2019-08-29
NZ624057A (en) 2016-08-26
ES2741476T3 (es) 2020-02-11
AU2017248451A1 (en) 2017-11-02
JP2018027968A (ja) 2018-02-22
AU2017248451B2 (en) 2019-11-14
JP2022123073A (ja) 2022-08-23
NZ737403A (en) 2020-05-29
US20140335072A1 (en) 2014-11-13
DK2768523T3 (da) 2019-07-22
BR112014009785B1 (pt) 2020-06-30
EP3581199B1 (en) 2023-05-31
DK3581199T3 (da) 2023-09-04
JP2020158521A (ja) 2020-10-01
MX392388B (es) 2025-03-24
WO2013059619A1 (en) 2013-04-25
AU2022202987A1 (en) 2022-05-26
CA2852942C (en) 2023-01-10
JP2024123126A (ja) 2024-09-10
HK1201439A1 (en) 2015-09-04
NZ722722A (en) 2019-05-31
EP2768523B1 (en) 2019-05-22
AU2025204462A1 (en) 2025-07-03
BR112014009785A8 (pt) 2020-02-27
AU2016202026A1 (en) 2016-04-21
PT3581199T (pt) 2023-08-31
NZ769098A (en) 2022-03-25
AU2022202987B2 (en) 2025-03-20
CA2852942A1 (en) 2013-04-25
AU2020200763B2 (en) 2022-05-26
HUE044650T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
AR084938A1 (es) Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112014015955A8 (pt) uso terapêutico subcutâneo de inibidor de dpp-4
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
BR112014014529A2 (pt) métodos para melhorar terapias médicas
CL2009002183A1 (es) Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica.
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112015018418A2 (pt) métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
MX350666B (es) Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
AR088204A1 (es) Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina
UY31826A (es) Compuesto peptídico y su uso
MX2014010989A (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos.
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
DOP2013000004A (es) Agentes terapeuticos 976